Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grassley repeats plea for permanent FDA commissioner

This article was originally published in The Gray Sheet

Executive Summary

"The agency needs and deserves a full-time, permanent Commissioner with the authority to address the cultural, structural and scientific challenges that have plagued the agency," Senate Finance Committee Chair Chuck Grassley (R-Iowa) states in a Feb. 3 letter to White House Chief of Staff Andrew Card. Following Lester Crawford's abrupt departure in September and President Bush's selection of National Cancer Institute Director Andrew von Eschenbach as FDA acting commissioner, Grassley urged the President to select a permanent replacement (1"The Gray Sheet" Oct. 3, 2005, p. 3). In January, Crawford joined the lobbying firm Policy Directions as senior counsel. The firm counts the Pharmaceutical Research & Manufacturers of America, the Biotechnology Industry Organization and many pharmaceutical companies as clients. Baxter and Bausch & Lomb have also used its services...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel